1 Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.
2 Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.
J Manag Care Spec Pharm. 2018 Nov;24(11):1184-1196. doi: 10.18553/jmcp.2018.24.11.1184.
Current evidence of the effects of pharmacy services on asthma outcomes are not conclusive, since most pharmacy services comprise a variety of interventions.
To assess the effect of a service containing self-management support delivered by community pharmacists to patients with asthma.
A systematic search was performed in the following databases from inception to January 2017: PubMed, Embase, Cochrane Library's Central Register of Controlled Trials, CINAHL (Cumulative Index to Nursing and Allied Health Literature) Plus, International Pharmaceutical Abstracts, and PsycInfo. Original studies were selected if they met the following criteria: (a) provided by community pharmacists; (b) the intervention service included the essential components of asthma self-management; (c) included a usual care group; and (d) measured control/severity of asthma symptoms, health-related quality of life (HRQOL), or medication adherence.
Of the 639 articles screened, 12 studies involving 2,121 asthma patients were included. Six studies were randomized trials, and the other 6 were nonrandomized trials. Patients with asthma who received a self-management support service by community pharmacists had better symptom control/lower severity compared with those receiving usual care (standardized mean difference [SMD] = 0.46; 95% CI = 0.09-0.82) with high heterogeneity (I=82.6%; P = 0.000). The overall improvement in HRQOL and medication adherence among patients in the asthma self-management support group was greater than for those in the usual care group with SMD of 0.23 (95% CI = 0.12-0.34) and 0.44 (95% CI = 0.27-0.61), respectively. Evidence of heterogeneity was not observed in these 2 outcomes.
Self-management support service provided by community pharmacists can help improve symptom control, quality of life, and medication adherence in patients with asthma.
This study received financial support from Naresuan University's Faculty of Pharmaceutical Sciences Research Fund. Two authors, Saini and Krass, have studies that were included in this review. However, they were not involved in the processes that could bias outcomes of the present study, that is, quality assessment and meta-analysis. The remaining authors have declared no conflicts of interest.
目前,关于药学服务对哮喘结局影响的证据尚不确定,因为大多数药学服务包含各种干预措施。
评估由社区药剂师向哮喘患者提供自我管理支持服务的效果。
从建库至 2017 年 1 月,我们在以下数据库中进行了系统检索:PubMed、Embase、Cochrane 图书馆对照试验中心注册库、CINAHL(护理与联合健康文献累积索引)、国际药学文摘和 PsycInfo。如果原始研究符合以下标准,则将其纳入:(a)由社区药剂师提供;(b)干预服务包括哮喘自我管理的基本组成部分;(c)包括常规护理组;(d)测量哮喘症状的控制/严重程度、健康相关生活质量(HRQOL)或药物依从性。
在筛选出的 639 篇文章中,纳入了 12 项涉及 2121 例哮喘患者的研究。6 项研究为随机试验,其余 6 项为非随机试验。与接受常规护理的患者相比,接受社区药剂师自我管理支持服务的哮喘患者的症状控制更好/严重程度更低(标准化均数差 [SMD] = 0.46;95%CI = 0.09-0.82),且存在高度异质性(I=82.6%;P = 0.000)。在哮喘自我管理支持组中,患者的 HRQOL 和药物依从性总体改善情况大于常规护理组,SMD 分别为 0.23(95%CI = 0.12-0.34)和 0.44(95%CI = 0.27-0.61)。在这两个结果中未观察到异质性证据。
社区药剂师提供的自我管理支持服务可帮助改善哮喘患者的症状控制、生活质量和药物依从性。
本研究得到纳瑞宣大学药学院研究基金的支持。两位作者 Saini 和 Krass 的研究被纳入了本综述。然而,他们没有参与可能影响本研究结果的过程,即质量评估和荟萃分析。其余作者均声明不存在利益冲突。